ClinicalTrials.gg
Not yet recruitingNCT07555054Updated Apr 28, 2026

A Study of the Effect and Safety of HS-10390 in the Treatment of Participants With Chronic Kidney Disease

A Phase 2 interventional study of HS-10390 and HS-10390 in Chronic Kidney Disease, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-04-28.

Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
182
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 245 studies in Renal Insufficiency, Chronic with a site in China — 94 open to participants now, 107 under way, 17 of them phase 3. Renal Insufficiency, Chronic · China.

Planned enrollment
82nd of 164
182 · median 182
Started
2026
with 26 others
Phase 2
22 of 245
5 open now
Primary completion
2027-11
later than 64 of 106 live
Registered
225th of 245
by date

Among the 245 studies in Renal Insufficiency, Chronic with a site in China, this one is the 82nd largest by planned enrollment of the 164 interventional ones that give a count, is one of 27 that started in 2026, is one of 22 in phase 2, reaches primary completion later than 64 of the 106 other live ones, and was the 225th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

94 of the 245 studies in Renal Insufficiency, Chronic with a site in China are open now. Recruiting first, the newest first:

89 more — sign in →

All 94 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 435 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 111 (26%) stop at 75 or younger; 45 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 245 studies in Renal Insufficiency, Chronic with a site in China, or all of them as a file.
02

Study summary

The purpose of the study was to evaluate the efficacy and safety of HS-10390 in participants with chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR) ≥ 30 and \<90 mL/min/1.73 m\^2, and urinary albumin to creatinine ratio (UACR) ≥ 150 mg/g and \< 3000 mg/g

03

Conditions studied

  • Chronic Kidney Disease

Keywords

  • chronic kidney disease
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and women aged 18-70 years old;
  2. (BMI) ≥18.0 and \<50.0 kg/m\^2 at screening;
  3. Currently on stable dose (maximum tolerated dose and at least one-half of the maximum labeled dose) of ACEI and/or ARB therapy for at least 4 weeks and treated for at least 3 months prior to the screening visit;
  4. Diagnosed with chronic kidney disease, and the estimated (eGFR) was ≥30 and \<90 mL/min/1.73 m\^2 calculated using the 2021 CKD-EPI creatine formula at screening;
  5. Urinary albumin/creatinine ratio (UACR) was ≥300 and \<3000 mg/g for at least 2 times on different days detected by the local laboratory at screening;
  6. Systolic BP between 90 and 160 mmHg and diastolic BP between 60 and 100 mmHg;
  7. Agree to .

Exclusion criteria

Exclusion Criteria:

  1. A known or suspected allergy to the medical drug or its components or ;
  2. Within 4 weeks before screening, the following drugs could not maintain the stable regimen: diabetes drugs, hypertension drugs, non-steroidal anti-inflammatory drugs;
  3. If glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are prescribed, the dose are unstable within 8 weeks before screening ;
  4. Participants with uncontrolled diabetes mellitus ( > 8%);
  5. Received any other study drug treatment within 30 days or 5 half-lives (whichever is longer) prior to screening;
  6. Polycystic kidney disease, lupus nephritis, anti-neutrophil cytoplasmic antibody (ANCA) -associated vasculitis, acute glomerulonephritis, bilateral renal artery stenosis;
  7. Acute kidney injury or dialysis treatment within 6 months before screening;
  8. Received kidney transplant, or plan to receive kidney transplant during the trial;
  9. \< 100×10\^9/L or value \< 90 g/L or Hematocrit value \< 27% (0.27 V/V) at screening;
  10. Elevations of transaminases ( and/or AST) >3 times (ULN) or total exceeding 1.5 times the upper limit of normal at screening;
  11. Serum potassium >5.5 mmol/L at screening.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
182 participants (estimated)

Study arms

  • Experimental
    HS-10390 Dose A

    HS-10390 Dose A

    Drug: HS-10390

  • Experimental
    HS-10390 Dose B

    HS-10390 Dose B

    Drug: HS-10390

  • Experimental
    HS-10390 Dose C

    HS-10390 Dose C

    Drug: HS-10390

  • Active comparator
    Irbesartan

    Irbesartan will be administered daily as a 150-mg oral tablet. Irbesartan will be administered daily as a 150-mg orally for the first 2 weeks of the study following randomization. For patients who tolerate the initial dose of 150 mg after 2 weeks will increase their dose to 300 mg.

    Drug: Irbesartan

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Urinary Albumin to Creatinine Ratio (UACR) From Baseline to Week 12

    Time frame: Frame: From baseline (Day 1) until Week 12 (Day 85)

Secondary outcomes

  1. Proportion of participants achieving ≥20%, ≥30%, and ≥40% reduction in UACR from baseline at week 12

    Time frame: From baseline (Day 1) until Week 12 (Day 85)

  2. Change in Urine Protein/Creatinine Ratio (UPCR) From Baseline at Each Visit

    Time frame: From baseline (Day 1) at each visit

  3. Change in 24 hour Urinary Protein Excretion From Baseline at Each Visit

    Time frame: From baseline (Day 1) at Each Visit

  4. Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline at Each Visit

    Time frame: From baseline (Day 1) at Each Visit

  5. Change in Office Systolic and Diastolic Blood Pressure From Baseline at Each Visit

    Time frame: From baseline (Day 1) at Each Visit

  6. Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)

    Time frame: From screening until Follow-up visit (Day 98)

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Nov 2027, 17 months later.

Of 80 industry-sponsored phase 2 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's planned 17 months is below that.

Counting every sponsor, half of 139 studies reached it within 25 months; a quarter within 15 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2026
First posted
Apr 28, 2026
StartEst.
May 21, 2026
Primary completionEst.
Nov 11, 2027
CompletionEst.
Dec 31, 2028
Last update
Apr 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07555054
Responsible party
Sponsor
First posted
Apr 28, 2026
Start date
May 21, 2026 (estimated)
Primary completion
Nov 11, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Apr 28, 2026

Study contacts

Wei Chen Professor, MD
Contact
Emailwchen66@qq.com
13924150966

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HS-10390

Start the discussion